We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

This study is currently recruiting participants.
Verified November 2017 by Puma Biotechnology, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02400476
First Posted: March 27, 2015
Last Update Posted: November 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Puma Biotechnology, Inc.
February 17, 2015
March 27, 2015
November 10, 2017
February 2015
January 2019   (Final data collection date for primary outcome measure)
Incidence of Grade 3 or higher diarrhea [ Time Frame: Length of study (15 months) ]
The primary objective of this study is to characterize the incidence and severity of diarrhea in patients with early-stage HER2 overexpressed/amplified (HER2+) breast cancer treated with neratinib when administered with intensive loperamide prophylaxis, after prior treatment with trastuzumab.
Incidence/Severity of diarrhea captured in the clinical study database [ Time Frame: Entire length of study (15 months) ]
Review of the incidence and severity of diarrhea.
Complete list of historical versions of study NCT02400476 on ClinicalTrials.gov Archive Site
  • Incidence and severity of diarrhea by loperamide exposure [ Time Frame: Length of study (15 months) ]
    Evaluate the association between loperamide exposure and the incidence and severity of diarrhea, with and without anti -inflammatory agents; with and without a bile acid sequestrant
  • Incidence of serious adverse events and other adverse events of special interest [ Time Frame: Length of study (15 months) ]
    Assess the incidence of serious adverse events (SAEs) and other adverse events of special interest (AESI)
  • Frequency distribution of maximum grade incidence of diarrhea [ Time Frame: Length of study (15 months) ]
    Review of the frequency distribution of the maximum grade incidence of diarrhea; incidence of serious adverse events (SAEs) and adverse events of special interest (AEOIs).
  • Incidence of diarrhea by loperamide exposure [ Time Frame: Length of study (15 months) ]
    Review of the incidence and severity of diarrhea by loperamide exposures; incidence of SAEs and AEOIs.
  • Severity of diarrhea by loperamide exposure [ Time Frame: Length of study (15 months) ]
    Review of the incidence and severity of diarrhea by loperamide exposures; incidence of SAEs and AEOIs.
Not Provided
Not Provided
 
A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Intensive Loperamide Prophylaxis
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

An open-label, Phase 2 study that will investigate the incidence of diarrhea in HER2+ breast cancer patients receiving neratinib with intensive loperamide diarrhea prophylaxis, alone and in combination with anti-inflammatory treatment, who have previously undergone a course of trastuzumab therapy in the adjuvant setting

Patients will receive:

  • Neratinib 240 mg orally once daily for thirteen (13) 28-day cycles
  • Loperamide daily for two (2) 28-day cycles and then as needed, or loperamide for 1 cycle [28 days] starting with the treatment group receiving colestipol under Amendment 4, and then as needed thereafter
  • Either an anti-inflammatory treatment for 1 cycle (for patients enrolled starting with Amendment 3), or a bile acid sequestrant treatment for 1 cycle (starting with the treatment group receiving colestipol under Amendment 4)
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Early Stage HER2+ Breast Cancer
  • Drug: Neratinib
    neratinib 240 mg (full treatment as extended adjuvant treatment for 13 cycles)
  • Drug: Loperamide
    intensive loperamide prophylaxis for two 28 day cycles (total 56 days) for neratinib and loperamide arm and budesonide arm, or 28 days for colestipol and bismuth subsalicylate or mesalamine arms
  • Drug: Budesonide
    budesonide extended release tablets 9 mg once daily with or without food for 28 days
  • Drug: Colestipol
    colestipol 2 g twice daily with or without food for 28 days
  • Drug: Bismuth Subsalicylate or Mesalamine
    bismuth subsalicylate 262 mg 3 times per day or mesalamine 2.4 g/day with food, for 28 days
  • Experimental: neratinib, loperamide and budesonide
    neratinib and intensive loperamide prophylaxis in combination with budesonide
    Interventions:
    • Drug: Neratinib
    • Drug: Loperamide
    • Drug: Budesonide
  • Experimental: neratinib, loperamide and colestipol
    neratinib and intensive loperamide prophylaxis in combination with colestipol
    Interventions:
    • Drug: Neratinib
    • Drug: Loperamide
    • Drug: Colestipol
  • Experimental: neratinib, loperamide and bismuth subsalicylate or mesalamine
    neratinib and intensive loperamide prophylaxis in combination with bismuth subsalicylate or mesalamine
    Interventions:
    • Drug: Neratinib
    • Drug: Loperamide
    • Drug: Bismuth Subsalicylate or Mesalamine
  • Experimental: neratinib, loperamide
    neratinib and intensive loperamide prophylaxis
    Interventions:
    • Drug: Neratinib
    • Drug: Loperamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
240
April 2019
January 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Aged ≥18 years at signing of informed consent
  2. Histologically confirmed stage 1 through stage 3c primary adenocarcinoma of the breast
  3. Documented HER2 overexpression or gene-amplified tumor by a validated approved method
  4. Patients must have completed a course of prior adjuvant trastuzumab or experienced side effects that resulted in early discontinuation of trastuzumab that have since resolved
  5. The last dose of trastuzumab must have been given >2 weeks and ≤1 year (365 days) from enrollment
  6. Clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry, including

    • Bone scan or positron emission tomography (PET) scan; required only if alkaline phosphatase (ALP) is ≥2 x upper limit of normal (ULN) and/or there are symptoms of metastatic bone disease. A confirmatory imaging study is required if the results from the bone scan are questionable
    • Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the abdomen and chest; required only if aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or ALP is ≥2 x ULN
    • Chest radiograph
  7. Left ventricular ejection fraction (LVEF) ≥50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
  8. Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
  9. Negative β-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause. [Women are considered postmenopausal if they are ≥12 months without menses, in the absence of endocrine or anti-endocrine therapies.]
  10. Women of childbearing potential must agree and commit to the use of a highly effective non-hormonal method of contraception, ie, intrauterine device, bilateral tubal ligation, vasectomized partner, or abstinence (only when it is the preferred lifestyle of the patient), from the time of informed consent until 28 days after the last dose of the investigational products. Men and their female partners of childbearing potential must agree and commit to use a highly effective method of contraception (ie, any of the above methods or hormonal contraception associated with inhibition of ovulation) while on treatment and for 3 months after last dose of investigational products
  11. Recovery (ie, to Grade 1 or baseline) from all clinically significant AEs related to prior therapies (excluding alopecia, neuropathy, and nail changes)
  12. Provide written, informed consent to participate in the study and follow the study procedures

Exclusion Criteria:

  1. Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease prior to or at the time of study entry
  2. Currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer
  3. Major surgery within <30 days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy, except hormonal therapy (eg, tamoxifen, aromatase inhibitors), <14 days prior to the initiation of investigational products
  4. Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2; including individuals who currently use digitalis, beta -blockers, or calcium channel blockers specifically for congestive heart failure), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia
  5. QTc interval >0.450 seconds (males) or >0.470 (females), or known history of QTc prolongation or Torsade de Pointes (TdP)
  6. Screening laboratory assessments outside the following limits:

    Absolute neutrophil count (ANC) <1,000/μl (<1.0 x 109/L) Platelet count <100,000/μl (<100 x 109/L) Hemoglobin <9 g/dL Total bilirubin >1.5 x institutional upper limit of normal (ULN) (i n case of known Gilbert's syndrome, <2 x ULN is allowed) Creatinine Creatinine clearance <30 mL/min (as calculated by Cockcroft-Gault formula or Modification of Diet in Renal Disease [MDRD] formula)

  7. Active, unresolved infections
  8. Patients with a second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Patients with other non-mammary malignancies must have been disease-free for at least 5years
  9. Currently pregnant or breast-feeding
  10. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or Grade ≥2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline)
  11. Clinically active infection with hepatitis B or hepatitis C virus
  12. Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the Investigator's judgment, make the patient inappropriate for this study
  13. Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial
  14. Unable or unwilling to swallow tablets
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Puma Biotechnology, Inc. (424) 248-6500 clinicaltrials@pumabiotechnology.com
Australia,   Canada,   United States
 
 
NCT02400476
PUMA-NER-6201
Not Provided
Not Provided
Not Provided
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Not Provided
Not Provided
Puma Biotechnology, Inc.
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP